多发性硬化症药物在代表性不足的群体中有益

IF 28.2 1区医学 Q1 CLINICAL NEUROLOGY Nature Reviews Neurology Pub Date : 2025-01-17 DOI:10.1038/s41582-025-01060-3

Ian Fyfe

{"title":"多发性硬化症药物在代表性不足的群体中有益","authors":"Ian Fyfe","doi":"10.1038/s41582-025-01060-3","DOIUrl":null,"url":null,"abstract":"<p>Real-world data indicate that ocrelizumab is safe and effective in Latino people with multiple sclerosis (MS), according to a recent report. In a prospective observational study, a total of 305 people with relapsing–remitting MS, primary progressive MS or secondary progressive MS received ocrelizumab during a median follow-up period of 29.5 months. Only one person experienced a relapse, and disability worsened in only 12.4% of participants overall, with the highest risk in the group with secondary progressive MS. The findings provide evidence for efficacy and safety in a group that has been underrepresented in clinical trials of the drug.</p>","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"54 1","pages":""},"PeriodicalIF":28.2000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MS drug beneficial in an underrepresented group\",\"authors\":\"Ian Fyfe\",\"doi\":\"10.1038/s41582-025-01060-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Real-world data indicate that ocrelizumab is safe and effective in Latino people with multiple sclerosis (MS), according to a recent report. In a prospective observational study, a total of 305 people with relapsing–remitting MS, primary progressive MS or secondary progressive MS received ocrelizumab during a median follow-up period of 29.5 months. Only one person experienced a relapse, and disability worsened in only 12.4% of participants overall, with the highest risk in the group with secondary progressive MS. The findings provide evidence for efficacy and safety in a group that has been underrepresented in clinical trials of the drug.</p>\",\"PeriodicalId\":19085,\"journal\":{\"name\":\"Nature Reviews Neurology\",\"volume\":\"54 1\",\"pages\":\"\"},\"PeriodicalIF\":28.2000,\"publicationDate\":\"2025-01-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41582-025-01060-3\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41582-025-01060-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

根据最近的一份报告，实际数据表明ocrelizumab对拉丁美洲多发性硬化症（MS）患者是安全有效的。在一项前瞻性观察性研究中，共有305名复发缓解型MS、原发性进行性MS或继发性进行性MS患者在29.5个月的中位随访期间接受了ocrelizumab治疗。只有一人复发，只有12.4%的参与者残疾恶化，继发性进展性ms组的风险最高。研究结果为该药物在临床试验中代表性不足的组的有效性和安全性提供了证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

MS drug beneficial in an underrepresented group

Real-world data indicate that ocrelizumab is safe and effective in Latino people with multiple sclerosis (MS), according to a recent report. In a prospective observational study, a total of 305 people with relapsing–remitting MS, primary progressive MS or secondary progressive MS received ocrelizumab during a median follow-up period of 29.5 months. Only one person experienced a relapse, and disability worsened in only 12.4% of participants overall, with the highest risk in the group with secondary progressive MS. The findings provide evidence for efficacy and safety in a group that has been underrepresented in clinical trials of the drug.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Neurology 医学-临床神经学

CiteScore

29.90

自引率

0.80%

发文量

138

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Neurology aims to be the premier source of reviews and commentaries for the scientific and clinical communities we serve. We want to provide an unparalleled service to authors, referees, and readers, and we work hard to maximize the usefulness and impact of each article. The journal publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians working in the field of neurology. Our broad scope ensures that the work we publish reaches the widest possible audience. Our articles are authoritative, accessible, and enhanced with clearly understandable figures, tables, and other display items. This page gives more detail about the aims and scope of the journal.

期刊最新文献

Imperatives and co-benefits of research into climate change and neurological disease Markers help to predict dementia with Lewy bodies MS drug beneficial in an underrepresented group Neuron–tumour networks targeted Brain stimulation aids walking after spinal injury